<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01159847</url>
  </required_header>
  <id_info>
    <org_study_id>EFSD DPP-Ⅳ LADA</org_study_id>
    <nct_id>NCT01159847</nct_id>
  </id_info>
  <brief_title>Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes(LADA)</brief_title>
  <acronym>DPP-ⅣLADA</acronym>
  <official_title>Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes(LADA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Foundation for the Study of Diabetes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Medical Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Foundation for the Study of Diabetes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the protective effects of sitagliptin on β cell
      function in patients with adult-onset latent autoimmune diabetes (LADA) and its mechanisms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult-onset latent autoimmune diabetes (LADA), etiologically belongs to type 1 diabetes
      (T1D), is characterized by the presence of islet autoantibodies, such as islet cell antibody
      (ICA) and glutamic acid decarboxylase antibody (GADA), and prones to develop β-cell failure.
      The goals of treatment for LADA are suppression of autoimmune β cell destruction,
      preservation of islet function and prevention of diabetic complications. Recently two classes
      of compounds have been approved by the FDA as T2D therapeutics: the glucagon-like peptide-1
      (GLP-1) receptor agonist (incretin mimetic) exenatide (Byetta) and the dipeptidyl peptidase
      IV (DPP-IV) inhibitor sitagliptin (Januvia) and vildagliptin (Galvus). They have been shown
      to reduce HbA1c, fasting glucose and to improve β cell function in T2D patients, as a
      mono-therapy or in combination with metformin or thizolidinediones. Besides, in vitro studies
      showed incretin-based therapy can stimulate β-cell proliferation and survival, increase β
      cell insulin content and inhibit apoptosis. Moreover, several short-term pilot studies
      suggest GLP-1 may also have the potential for treating T1D. Several findings suggest that
      Ex-4 may also act as a regulator of the immune response in addition to its potential effects
      on β cell proliferation. Therefore, we hypothesized DPP-IV inhibitors might provide
      therapeutic advantages in T1D though no study has been reported. Besides the β cell function,
      another important target is insulin sensitivity. As for DPP-IV inhibitor, clinical trials
      demonstrated their beneficial effects on insulin sensitivity in subjects with T2D and IFG and
      indiabetic rat model. We'd like to further explore the possible effect of sitagliptin on
      insulin sensitivity in LADA patients by HOMA-IR index and euglycemic clamp technique. In
      addition, the systemic inflammation associated with a wide array of plasma proteins and
      pro-inflammatory cytokines(i.e., CRP, TNF-α, IL-6) play an additional role in the
      pathogenesis of insulin resistance in diabetes. It will be of interest to investigate the
      adipokines and proinflammmatory cytokines after the sitagliptin therapy in the study. Hence,
      we aim to explore the effects of sitagliptin plus insulin on β cell function, insulin
      sensitivity, pro-inflammatory cytokines and immune regulation including Teff and Treg
      frequency, and function in patients with LADA.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effects of sitagliptin on β cell function and insulin sensitivity of LADA patients</measure>
    <time_frame>2 years</time_frame>
    <description>The assessment of the change of β cell function in patients with LADA treated with sitagliptin or placebo plus insulin by the standardized mixed meal stimulation test and insulin sensitivity by HOMA-IR.
The assessment of the change of insulin sensitivity in LADA patients by sequential insulin infusion with the euglycemic glucose clamp technique and β cell function (first-phase insulin release, FPIR) will be assessed using intravenous glucose tolerance test (IVGTT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The possible immunomodulatory effects of sitagliptin on LADA patients</measure>
    <time_frame>2 years</time_frame>
    <description>The change of the frequency of pathogenic Teff (CD4+Th1, Th2, Th17 and CD8+) cells and CD4+CD25+Foxp3+Tregs before and after sitagliptin treatment in LADA patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The possible immunomodulatory effects of sitagliptin on LADA patients</measure>
    <time_frame>2 years</time_frame>
    <description>Effect of sitagliptin on cytokine production of Teff and Tregs before and after sitagliptin treatment in LADA patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The possible immunomodulatory effects of sitagliptin on LADA patients</measure>
    <time_frame>2 years</time_frame>
    <description>Effect of sitagliptin on Foxp3 mRNA expression of Tregs and RORγT mRNA expression of Th17 cells before and after sitagliptin treatment in LADA patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The possible immunomodulatory effects of sitagliptin on LADA patients</measure>
    <time_frame>2 years</time_frame>
    <description>The comparison of GAD65 reactive IFN-γ-Th1, IL-4-Th2, IL-17-Th17 and IL-10-Treg cells detected by ELISPOT before and after sitagliptin treatment in LADA patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The possible immunomodulatory effects of sitagliptin on LADA patients</measure>
    <time_frame>2 years</time_frame>
    <description>The change of the adiponectin, IL-6, IL-17 and CRP etc. before and after the sitagliptin treatment in LADA patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sitagliptin combined with insulin therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin</intervention_name>
    <description>sitagliptin tablet,100 mg p.o. qd,2 year</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_label>insulin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diabetes diagnosed according to the report of WHO in 1999.

          2. Age at onset between 25~70 years.

          3. Disease duration of less than 3 year.

          4. No ketoacidosis within the first 6 months after diagnosis of diabetes.

          5. GADA positive twice within one month.

          6. FCP level of 0.2 nmol/L or more.

        Exclusion Criteria:

          1. Insulin requirements more than 0.8 units/kg/day.

          2. Evidence of chronic infection or acute infection affected blood glucose control within
             4 weeks prior to visit 1.

          3. History of any malignancy.

          4. Pregnancy, breastfeeding or planned pregnancy within two years.

          5. Secondary diabetes.

          6. Congestive heart failure requiring pharmacologic treatment.

          7. Renal disease or renal dysfunction or diabetic nephropathy suggested by serum
             creatinine levels≥1.5 mg/dL (132μmol/L) for males and ≥1.4mg/dL (123μmol/L) for
             females or abnormal creatinine clearance at Visit 1.

          8. Concurrent medical condition that may interfere with the interpretation of efficacy
             and safety data during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiguang Zhou, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Center, Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Center, Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes. 1993 Feb;42(2):359-62.</citation>
    <PMID>8425674</PMID>
  </reference>
  <reference>
    <citation>Dupre J. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Regul Pept. 2005 Jun 15;128(2):149-57. Review. Erratum in: Regul Pept. 2006 Mar 15;134(1):67-8.</citation>
    <PMID>15780434</PMID>
  </reference>
  <reference>
    <citation>Dupre J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P, McDonald TJ. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes. 1995 Jun;44(6):626-30.</citation>
    <PMID>7789625</PMID>
  </reference>
  <reference>
    <citation>Behme MT, Dupré J, McDonald TJ. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC Endocr Disord. 2003 Apr 10;3(1):3.</citation>
    <PMID>12697069</PMID>
  </reference>
  <reference>
    <citation>Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care. 1996 Jun;19(6):580-6.</citation>
    <PMID>8725855</PMID>
  </reference>
  <reference>
    <citation>Zhang J, Tokui Y, Yamagata K, Kozawa J, Sayama K, Iwahashi H, Okita K, Miuchi M, Konya H, Hamaguchi T, Namba M, Shimomura I, Miyagawa JI. Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes. Diabetologia. 2007 Sep;50(9):1900-1909. doi: 10.1007/s00125-007-0737-6. Epub 2007 Jul 14.</citation>
    <PMID>17632702</PMID>
  </reference>
  <reference>
    <citation>Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CH, Pederson RA. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003 Mar;52(3):741-50.</citation>
    <PMID>12606516</PMID>
  </reference>
  <reference>
    <citation>Pospisilik JA, Ehses JA, Doty T, McIntosh CH, Demuth HU, Pederson RA. Dipeptidyl peptidase IV inhibition in animal models of diabetes. Adv Exp Med Biol. 2003;524:281-91.</citation>
    <PMID>12675250</PMID>
  </reference>
  <reference>
    <citation>Kim SJ, Nian C, Doudet DJ, McIntosh CH. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes. 2008 May;57(5):1331-9. doi: 10.2337/db07-1639. Epub 2008 Feb 25.</citation>
    <PMID>18299314</PMID>
  </reference>
  <reference>
    <citation>Flentke GR, Munoz E, Huber BT, Plaut AG, Kettner CA, Bachovchin WW. Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1556-9.</citation>
    <PMID>1671716</PMID>
  </reference>
  <reference>
    <citation>Reinhold D, Bank U, Bühling F, Lendeckel U, Faust J, Neubert K, Ansorge S. Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells. Immunology. 1997 Jul;91(3):354-60.</citation>
    <PMID>9301523</PMID>
  </reference>
  <reference>
    <citation>Kähne T, Neubert K, Faust J, Ansorge S. Early phosphorylation events induced by DPIV/CD26-specific inhibitors. Cell Immunol. 1998 Oct 10;189(1):60-6.</citation>
    <PMID>9758695</PMID>
  </reference>
  <reference>
    <citation>Yang Z, Zhou Z, Huang G, Ling H, Yan X, Peng J, Li X. The CD4(+) regulatory T-cells is decreased in adults with latent autoimmune diabetes. Diabetes Res Clin Pract. 2007 Apr;76(1):126-31. Epub 2006 Sep 26.</citation>
    <PMID>17005288</PMID>
  </reference>
  <reference>
    <citation>Xue S, Wasserfall CH, Parker M, Brusko TM, McGrail S, McGrail K, Moore M, Campbell-Thompson M, Schatz DA, Atkinson MA, Haller MJ. Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency. Ann N Y Acad Sci. 2008 Dec;1150:152-6. doi: 10.1196/annals.1447.049.</citation>
    <PMID>19120286</PMID>
  </reference>
  <reference>
    <citation>Utzschneider KM, Tong J, Montgomery B, Udayasankar J, Gerchman F, Marcovina SM, Watson CE, Ligueros-Saylan MA, Foley JE, Holst JJ, Deacon CF, Kahn SE. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care. 2008 Jan;31(1):108-13. Epub 2007 Oct 1.</citation>
    <PMID>17909087</PMID>
  </reference>
  <reference>
    <citation>Ahrén B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care. 2005 Aug;28(8):1936-40.</citation>
    <PMID>16043735</PMID>
  </reference>
  <reference>
    <citation>Orskov L, Holst JJ, Møller J, Orskov C, Møller N, Alberti KG, Schmitz O. GLP-1 does not not acutely affect insulin sensitivity in healthy man. Diabetologia. 1996 Oct;39(10):1227-32.</citation>
    <PMID>8897012</PMID>
  </reference>
  <reference>
    <citation>Ahrén B, Larsson H, Holst JJ. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997 Feb;82(2):473-8.</citation>
    <PMID>9024239</PMID>
  </reference>
  <reference>
    <citation>Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002 Mar 9;359(9309):824-30.</citation>
    <PMID>11897280</PMID>
  </reference>
  <reference>
    <citation>Pospisilik JA, Stafford SG, Demuth HU, McIntosh CH, Pederson RA. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes. 2002 Sep;51(9):2677-83.</citation>
    <PMID>12196458</PMID>
  </reference>
  <reference>
    <citation>Pietropaolo M, Barinas-Mitchell E, Kuller LH. The heterogeneity of diabetes: unraveling a dispute: is systemic inflammation related to islet autoimmunity? Diabetes. 2007 May;56(5):1189-97. Epub 2007 Feb 23. Review.</citation>
    <PMID>17322478</PMID>
  </reference>
  <reference>
    <citation>Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract. 2007 Sep;13(5):444-50.</citation>
    <PMID>17872344</PMID>
  </reference>
  <reference>
    <citation>Duttaroy A, Voelker F, Merriam LQ, et al. The DPP-4 inhibitor Vildagliptin increases pancreatic β-cell neogenesis and decreases apoptosis. Diabetes, 2005; 54 (Suppl. 1): A141.</citation>
  </reference>
  <reference>
    <citation>Yang ZF, Zhou ZG, Tang WL, Huang G, Peng J, Li X, He L. [Decrease of FOXP3 mRNA in CD4+ T cells in latent autoimmune diabetes in adult]. Zhonghua Yi Xue Za Zhi. 2006 Sep 26;86(36):2533-6. Chinese.</citation>
    <PMID>17198560</PMID>
  </reference>
  <reference>
    <citation>Korom S, De Meester I, Stadlbauer TH, Chandraker A, Schaub M, Sayegh MH, Belyaev A, Haemers A, Scharpé S, Kupiec-Weglinski JW. Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation. 1997 May 27;63(10):1495-500.</citation>
    <PMID>9175816</PMID>
  </reference>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2010</study_first_submitted>
  <study_first_submitted_qc>July 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <last_update_submitted>July 9, 2010</last_update_submitted>
  <last_update_submitted_qc>July 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Zhiguang Zhou/Director, Department of Endocrinology, Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University; Head, Diabetes Center, Central South University</name_title>
    <organization>Department of Endocrinology, Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University; Diabetes Center, Central South University</organization>
  </responsible_party>
  <keyword>sitagliptin</keyword>
  <keyword>LADA</keyword>
  <keyword>C-Peptide</keyword>
  <keyword>Flow Cytometry</keyword>
  <keyword>ELISPOT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

